Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $25.05 Analyst target: $68.29 Upside: 172.61%
Rapport Therapeutics, Inc. is a pioneering biotechnology company dedicated to the advancement of therapeutics for neurodegenerative diseases, especially Alzheimer's and associated cognitive disorders. Utilizing proprietary drug candidates and cutting-edge technology platforms, the firm is focused on meeting significant unmet medical needs through comprehensive scientific research and clinical trials. With a robust pipeline of innovative treatment options, Rapport Therapeutics is strategically poised to reshape the treatment paradigm for individuals facing the challenges of cognitive impairments, enhancing patient quality of life and contributing to the broader healthcare landscape.
See the full interactive analysis & chart →Informational only — not investment advice.